Estradiol (Oestradiol, E2)

Oestradiol (E2) is the most potent of the three forms of oestrogen. In women it is produced primarily by the ovaries and varies dramatically across the menstrual cycle. In men it is produced by aromatisation of testosterone in fat, brain, bone and other tissues. Australian pathology labs report E2 in pmol/L; older US-style ng/dL or pg/mL conversions are sometimes seen on imported reports.

In women, oestradiol is central to assessing ovarian function, fertility, IVF response, perimenopause and menopause. In men on TRT, oestradiol is one of the most important markers to monitor: if it climbs too high (commonly >150-200 pmol/L on a sensitive assay) it can drive gynaecomastia, water retention, mood changes and erectile dysfunction; if it is suppressed too low it causes joint pain, low libido and accelerated bone loss. The aim on TRT is the mid-normal male range, achieved through dose splitting before reaching for an aromatase inhibitor.

In women, high oestradiol is normal mid-cycle and during ovarian stimulation for IVF. Outside that context, persistently elevated oestradiol can indicate ovarian cysts, granulosa cell tumours, oestrogen-secreting tumours, or exogenous oestrogen (HRT, oral contraceptives, environmental exposure). In men, high oestradiol is a frequent issue on testosterone replacement therapy (TRT) — testosterone is converted to oestradiol by the aromatase enzyme, especially in body fat. Common drivers are too-high TRT dose, infrequent injections (large peaks), high body fat percentage, excessive alcohol intake, and certain medications. Symptoms include water retention, gynaecomastia (breast tissue growth), nipple sensitivity, mood swings, low libido and erectile dysfunction. The first-line management is usually dose splitting (smaller, more frequent injections) and weight loss before considering an aromatase inhibitor.

In premenopausal women, low oestradiol can indicate hypothalamic amenorrhoea (often from undereating, overtraining or stress), premature ovarian insufficiency, polycystic ovary syndrome (in some patterns), or pituitary disease. In peri- and postmenopausal women, low E2 is physiological and underlies symptoms such as hot flushes, vaginal dryness, sleep disruption, mood changes and accelerated bone loss. In men, oestradiol that is suppressed too low (commonly <40 pmol/L) — typically from over-aggressive use of aromatase inhibitors on TRT — causes joint pain, low libido, fatigue, depressed mood, and accelerated bone density loss. The "lower is better" myth around male oestradiol is unsupported by evidence; the goal on TRT is the mid-normal male range, not the lowest possible.

Women being investigated for fertility, irregular cycles or menopausal symptoms should test oestradiol on day 2-4 of the cycle (or whenever symptomatic in postmenopausal women). On HRT, retest every 3-6 months until stable. On TRT for men, oestradiol should be tested at baseline, 6-8 weeks after starting or changing dose, and every 6-12 months once stable — always at trough (just before next injection) using a sensitive assay where possible. Athletes, anyone post-bariatric surgery and those with breast or prostate cancer history should follow specialist guidance.

In women: interpreted alongside FSH, LH, progesterone and AMH for fertility/menopause assessment. In men on TRT: interpreted alongside total and free testosterone, SHBG and haematocrit. CRP and liver enzymes are also relevant when interpreting unusual oestradiol levels.